• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Our people > Leadership > R&D
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
IsabelaRibeiro2019

Dr Isabela Ribeiro

Viral Diseases Cluster Director, DNDi

Dr Isabela Ribeiro joined DNDi as a Senior Project Manager in March 2007, after working as a consultant on DNDi projects since 2005. Previously Head of DNDi’s Chagas Clinical Programme and Head of Dynamic Portfolio Unit, Dr Ribeiro is now Viral Diseases Cluster Director.

Dr Ribeiro has over fourteen years of drug development experience with a focus on neglected diseases, most recently serving as a consultant to the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO-TDR).

With WHO-TDR, Dr Ribeiro contributed to several projects involving the management of large community-based clinical studies in endemic countries.

A member of the Scientific Advisory Committee of the PDTIS, Oswaldo Cruz Foundation, since 2005, Dr Ribeiro completed a post-doctoral fellowship in infectious diseases and an internal medicine residency at Ohio State University and worked as clinical research fellow based at the Communicable Disease Unit of St. George’s Hospital, London, after earning her MD from the Federal University of Rio de Janeiro in Brazil.

Featured news & publications

Loading...
  • A simulation-based method to inform serosurvey designs for estimating the force of infection using existing blood samples
  • Human Trypanosoma cruzi chronic infection leads to individual level steady-state parasitemia: Implications for drug-trial optimization in Chagas disease
  • A phase-2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease
  • Dengue, and the future of DNDi
  • Genetic polymorphism of Trypanosoma cruzi bloodstream populations in adult chronic indeterminate Chagas disease patients from the E1224 clinical trial
  • Managing snakebite
  • New chemotherapy regimens and biomarkers for Chagas disease: The rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia
  • Snakebites and COVID-19: two crises, one research and development opportunity
  • Serological reactivity against T. cruzi-derived antigens: evaluation of their suitability for the assessment of response to treatment in chronic Chagas disease
  • New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): A phase 2, double-blind, randomised trial

Featured events

Loading...
  • 22nd ICASA Conference
  • 9th International Conference on Infectious Disease Dynamics
  • Eleventh EDCTP Forum
  • AAPS 2023 PharmSci 360
  • Accelerating R&D for Snakebites: Building a Common Agenda for Progress

Our global footprint

Loading...
Doctors talking with patient in hospital

DNDi DRC

Female healthcare worker taking care of a little girl

DNDi Eastern Africa

Drug discovery activities

DNDi Japan

Female patient discussing with doctor

DNDi Latin America

Female doctor with a patient in a hospital

DNDi North America

Community worker talking with people in a rural village

DNDi South Asia

Malaysian doctor talking with a man in a hospital

DNDi South-East Asia

Little boy looking at the camera in a hospital

DNDi Southern Africa

Bernard Pécoul discussing with Joanne Liu at an event

DNDi Switzerland

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License